PHASE I STUDY OF GDC-0919 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTICANCER DRUGS IN PATIENTS WITH ADVANCED SOLID TUMORS
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 27 Jun 2017
At a glance
- Drugs Navoximod (Primary) ; Atezolizumab
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Chugai Pharmaceutical
- 21 Jun 2017 Planned number of patients changed from 30 to 42.
- 21 Jun 2017 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.
- 21 Jun 2017 Status changed from recruiting to active, no longer recruiting.